PepGen Inc. (PEPG)
D
Pipeline Grade
Financial Position (from SEC Filings)
$42.2M
Cash & Equivalents
$18.4M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$162M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-03-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07220603 | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) | PHASE2 | Recruiting | 48 |
| NCT06667453 | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | PHASE2 | Recruiting | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.